FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310127463> ?p ?o ?g. }

• W4310127463 endingPage "10433" @default.
• W4310127463 startingPage "10432" @default.
• W4310127463 abstract "Background: Sickle cell disease (SCD) is one of the most common genetic diseases globally. Clinical manifestations of SCD commonly include anemia, pain, vaso-occlusive events and cumulative end organ damage leading to significant morbidity and mortality. Historically, allogeneic hematopoietic cell transplantation (HCT) represented the only curative therapy for SCD, but is associated with significant HCT-related morbidity and mortality which limit its use (PMID: 8663884, PMID: 20007560). Autologous hematopoietic stem cell (HSC) -based gene therapies now offer curative potential with decreased toxicity (PMID: 28249145). However, effective HSC-based gene therapy depends on collection of sufficient HSCs (ideally >10x106 CD34+ cells/kg), typically from peripheral blood (PB) (PMID: 33956057). G-CSF and CXCR4 inhibition (CXCR4i) with plerixafor are the most widely used mobilization strategies (PMID: 19363221, PMID: 19720922). However, G-CSF is associated with risk of fatal vaso-occlusive events in SCD (PMID: 9734950, PMID: 11368061, PMID: 19513902). Meanwhile, short-acting CXCR4i with plerixafor alone does not reliably yield optimal HSC numbers for gene therapy applications (PMID: 30282642, PMID: 29419425, PMID: 29472357). Therefore, developing novel HSC mobilization regimens to rapidly and reliably mobilize optimal CD34+ HSCs for gene therapy in SCD represents an unmet need. Motixafortide (M) is a high-affinity, long-acting CXCR4 inhibitor. The recent Phase III, randomized, controlled GENESIS Trial demonstrated combination M+G-CSF resulted in 88.8% of patients collecting ≥6x106 CD34+ cells/kg (median 10.8x106) within 1 leukapheresis (LP) for HCT. This compares favorably to historical data with plerixafor+G-CSF where 54.2% collected to goal in 1 LP. Motixafortide also mobilized more immunophenotypically primitive HSCs and multi-potent progenitors compared to plerixafor. Meanwhile, transcriptional profiling by single-cell RNA sequencing revealed HSCs mobilized with M have gene expression profiles associated with enhanced regeneration and self-renewal, compared to G-CSF or plerixafor (DOI: 10.1182/blood-2021-144296). Motixafortide alone also mobilized an average of 11.6×106 CD34+ cells/kg in healthy volunteers, while mobilizing 91.6% of allogeneic HSC donors to goal in ≤2 LPs (median 6.07x106) (DOI: 10.1182/blood-2018-99-109701, PMID: 28835380). Natalizumab (N) is a monoclonal antibody to the a4 integrin subunit of a4b1 (VLA-4) capable of VLA4 inhibition (VLA4i). In mice and primates, N led to an ~8-fold increase in PB CD34+ HSCs in 24 hrs (PMID: 7692447). In humans, a single N infusion resulted in a 5- to 6-fold increase PB CD34+ HSCs. Meanwhile, the average PB CD34+ HSC levels after a single dose were similar to levels with repeated doses, indicating rapid mobilization of maximal PB HSCs by 24 hrs after N infusion (PMID: 18195093). Combination CXCR4i and VLA-4i has been well-tolerated and resulted in synergistic mobilization of HSCs in preclinical studies (PMID: 21886173). Therefore, we hypothesize that combination CXCR4i and VLA-4i with M+N represents a safe and effective strategy for robust, rapid and synergistic mobilization of HSCs to PB in patients with SCD. Study Design and Methods: This is a single center, single-arm, dose de-escalation, Phase 1 safety and feasibility study. Key eligibility criteria include patients with SCD (SS or Sβ0) age 18-35 years receiving automated RBC exchanges. Patients with prior HCT or gene therapy will be excluded. We estimate 5 patients in this pilot feasibility study will provide sufficient safety and preliminary efficacy data to guide further development of this novel mobilization strategy. All patients will have baseline labs prior to M (1.25mg/kg, subcutaneous), N (300mg, IV) and M+N dosing. Each patient will then undergo mobilization and LP (1 blood volume), per protocol (see Figure 1). The primary outcome will be to assess the safety and tolerability of M, N and M+N in each SCD patient, defined by dose-limiting toxicities and maximum tolerated dose. Key secondary outcomes include: kinetics of CD34+ HSC mobilization to PB (CD34+ cells/uL), number of CD34+ HSCs collected via LP (CD34+ cells/kg/L), incidence of AEs, pharmacokinetics and the recommended phase 2 dose. Correlative studies include immunophenotypic and single cell transcriptional profiling of CD34+ HSCs from LP product mobilized with M, N and M+N. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310127463 created "2022-11-30" @default.
• W4310127463 creator A5016869284 @default.
• W4310127463 creator A5016905580 @default.
• W4310127463 creator A5018160504 @default.
• W4310127463 creator A5018280436 @default.
• W4310127463 creator A5025524401 @default.
• W4310127463 creator A5028511278 @default.
• W4310127463 creator A5060952145 @default.
• W4310127463 creator A5065066309 @default.
• W4310127463 date "2022-11-15" @default.
• W4310127463 modified "2023-10-14" @default.
• W4310127463 title "A Phase I Safety and Feasibility Study to Evaluate Motixafortide (CXCR4/SDF-1 Inhibition) and Natalizumab (VLA-4/VCAM-1 Inhibition) As a Novel Regimen to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapy in Sickle Cell Disease" @default.
• W4310127463 doi "https://doi.org/10.1182/blood-2022-165454" @default.
• W4310127463 hasPublicationYear "2022" @default.
• W4310127463 type Work @default.
• W4310127463 citedByCount "0" @default.
• W4310127463 crossrefType "journal-article" @default.
• W4310127463 hasAuthorship W4310127463A5016869284 @default.
• W4310127463 hasAuthorship W4310127463A5016905580 @default.
• W4310127463 hasAuthorship W4310127463A5018160504 @default.
• W4310127463 hasAuthorship W4310127463A5018280436 @default.
• W4310127463 hasAuthorship W4310127463A5025524401 @default.
• W4310127463 hasAuthorship W4310127463A5028511278 @default.
• W4310127463 hasAuthorship W4310127463A5060952145 @default.
• W4310127463 hasAuthorship W4310127463A5065066309 @default.
• W4310127463 hasConcept C10205521 @default.
• W4310127463 hasConcept C109159458 @default.
• W4310127463 hasConcept C126322002 @default.
• W4310127463 hasConcept C129470790 @default.
• W4310127463 hasConcept C13373296 @default.
• W4310127463 hasConcept C159912055 @default.
• W4310127463 hasConcept C203014093 @default.
• W4310127463 hasConcept C2780640218 @default.
• W4310127463 hasConcept C2781004633 @default.
• W4310127463 hasConcept C28328180 @default.
• W4310127463 hasConcept C54355233 @default.
• W4310127463 hasConcept C71924100 @default.
• W4310127463 hasConcept C86803240 @default.
• W4310127463 hasConcept C8891405 @default.
• W4310127463 hasConceptScore W4310127463C10205521 @default.
• W4310127463 hasConceptScore W4310127463C109159458 @default.
• W4310127463 hasConceptScore W4310127463C126322002 @default.
• W4310127463 hasConceptScore W4310127463C129470790 @default.
• W4310127463 hasConceptScore W4310127463C13373296 @default.
• W4310127463 hasConceptScore W4310127463C159912055 @default.
• W4310127463 hasConceptScore W4310127463C203014093 @default.
• W4310127463 hasConceptScore W4310127463C2780640218 @default.
• W4310127463 hasConceptScore W4310127463C2781004633 @default.
• W4310127463 hasConceptScore W4310127463C28328180 @default.
• W4310127463 hasConceptScore W4310127463C54355233 @default.
• W4310127463 hasConceptScore W4310127463C71924100 @default.
• W4310127463 hasConceptScore W4310127463C86803240 @default.
• W4310127463 hasConceptScore W4310127463C8891405 @default.
• W4310127463 hasIssue "Supplement 1" @default.
• W4310127463 hasLocation W43101274631 @default.
• W4310127463 hasOpenAccess W4310127463 @default.
• W4310127463 hasPrimaryLocation W43101274631 @default.
• W4310127463 hasRelatedWork W1951809833 @default.
• W4310127463 hasRelatedWork W2044559595 @default.
• W4310127463 hasRelatedWork W2054167115 @default.
• W4310127463 hasRelatedWork W2061217297 @default.
• W4310127463 hasRelatedWork W2092193661 @default.
• W4310127463 hasRelatedWork W2092890208 @default.
• W4310127463 hasRelatedWork W2401815092 @default.
• W4310127463 hasRelatedWork W2565468786 @default.
• W4310127463 hasRelatedWork W4245863875 @default.
• W4310127463 hasRelatedWork W2095666245 @default.
• W4310127463 hasVolume "140" @default.
• W4310127463 isParatext "false" @default.
• W4310127463 isRetracted "false" @default.
• W4310127463 workType "article" @default.